Itchy skin all over: causes worth ruling out, and why treatment evidence is thin

Itch that spreads across the whole body, lasts weeks, and comes with no obvious rash is one of the more frustrating problems in medicine — for patients and doctors alike. It is common: population studies show that one in five people in the general population has had chronic pruritus at least once in their lifetime, with a 12-month incidence of 7% [s2]. The useful framing is that generalised itch is a symptom, not a diagnosis, and the first job is to find out whether something treatable is driving it.

What causes itching everywhere

Chronic pruritus means itch lasting more than six weeks [s3]. When it covers the whole body without a primary rash, the causes cluster into a few groups, and a proper work-up is aimed at telling them apart [s2]. Skin conditions such as eczema or scabies can itch before an obvious rash appears. Systemic diseases are the ones that matter most to exclude: kidney disease, liver and bile-flow (cholestatic) problems, thyroid disorders, iron deficiency, and blood disorders can all present as generalised itch. Neurological and drug causes account for more, and medicines are an easily missed trigger. In a meaningful share of people no cause is ever found — the origin of pruritus is unknown in 8% to 15% of affected patients [s1].

That last group has a name: chronic pruritus of unknown origin. Its prevalence among people with generalised itch ranges from 3.6% to 44.5%, and it is most common in older adults [s1] — which is why persistent all-over itch in an older person always deserves a look for an underlying cause rather than being written off as dry skin.

The uncomfortable truth about treatment evidence

Here is where honesty is required. A Cochrane review set out to assess treatments for chronic pruritus of unknown origin and found an almost empty cupboard. For the main interventions doctors actually reach for — emollient creams, cooling lotions, topical corticosteroids, topical antidepressants, systemic antihistamines, systemic antidepressants, systemic anticonvulsants and phototherapy — there was an absence of evidence, meaning no eligible trials at all [s1].

Only one study qualified, with 257 participants randomised (253 analysed), testing the drug serlopitant [s1]. Participants on serlopitant 5 mg may have had a greater rate of relief of self-reported itch intensity than those on placebo (risk ratio 2.06, 95% confidence interval 1.27 to 3.35), but this was low-certainty evidence, and the effects on quality of life, sleep and side effects were all rated very low certainty [s1]. The reviewers' blunt conclusion was that for most interventions of interest they found no studies, and that patients and clinicians may have to rely on indirect evidence from other forms of itch [s1].

That does not mean nothing works. It means the widely used treatments have not been properly tested in this specific condition. A 2026 systematic review that combed 228 records and included 52 sets out the options in current use — topical calcineurin inhibitors and capsaicin; systemic drugs such as JAK inhibitors, dupilumab and nemolizumab; the neuromodulators gabapentin and pregabalin; and phototherapy — while stressing that the treatment studies are of low quality with few randomised trials [s3]. Its account of why the skin itches when nothing is wrong with it points to a mix of immune (Th2), nerve-signalling and ageing-related changes, which is beginning to explain why newer immune-targeting drugs help some people [s3].

What the guidance actually advises

Because no single proven treatment exists, the European guideline advises a targeted, multimodal, step-wise approach: work up and treat any underlying disease first, then layer topical and systemic therapies to the individual [s2]. In practice that means generous emollients and gentle skin care as a base, breaking the itch-scratch cycle, treating any cause that is found, and escalating to prescription options — neuromodulators or the newer immune-targeting drugs — when simple measures fail. Recent years have brought genuinely new on-label therapies for specific itch conditions, including chronic prurigo and cholestatic pruritus [s2].

See a doctor promptly if all-over itch persists beyond a couple of weeks without an obvious skin cause, wakes you at night, or comes with weight loss, fatigue, fever, night sweats, yellowing of the skin or eyes, or swollen glands. Unexplained generalised itch can occasionally be the first sign of thyroid, liver, kidney or blood disorders — including, rarely, lymphoma — and those need testing, not another antihistamine.

This article is informational and is not medical advice.

Sources

• [s1] Interventions for chronic pruritus of unknown origin — Cochrane Database of Systematic Reviews, 25 January 2020. https://doi.org/10.1002/14651858.CD013128.pub2
• [s2] European Guideline on Chronic Pruritus — Acta Dermato-Venereologica, 22 August 2025. https://doi.org/10.2340/actadv.v105.44220
• [s3] Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review — International Journal of Dermatology, 13 January 2026. https://doi.org/10.1111/ijd.70259